Le Lézard
Classified in: Health
Subjects: AWD, NPT, HSP

The Leukemia & Lymphoma Society's Silicon Valley Chapter Announces Local 2019 Students of the Year Winners


SAN JOSE, Calif., March 14, 2019 /PRNewswire/ -- Through The Leukemia & Lymphoma Society's (LLS) Silicon Valley Students of the Year campaign presented by Silicon Valley Bank, more than 39 motivated high school students raised over $297,000 for LLS's cutting-edge cancer research and patient services. Pranav Aida, Abhinav Balla and Surya Sripathi of Team Cure Creators and freshman from Evergreen Valley High School, raised the most funds in Silicon Valley and earned the winning title, "Students of the Year." These fundraising superstars raised funds to support LLS's goal to find cures for blood cancers and ensure that patients have access to lifesaving treatments.

(PRNewsfoto/The Leukemia & Lymphoma Society)

Students of the Year is a seven-week philanthropic leadership development program during which students foster professional skills such as entrepreneurship, marketing, and project management in order to raise funds for LLS, the world's largest nonprofit fighting blood cancer. The title Student(s) of the Year is awarded to the candidate or co-candidates in each community who raises the most funds during the competition. Top local fundraisers become eligible to win the national title. The students raise money in honor of a local patient hero who is currently battling or is in remission from a blood cancer.

"Congratulations to Team Cure Creators and all our candidates, supporters and volunteers who helped to make Students of the Year a huge success," said Jeff Scanlan, Silicon Valley & Monterey Bay Area Chapter's Executive Director. "For these incredible individuals, it's not just about winning a title; it's all about the impact they are making in their communities and the generations ahead of them. From The Leukemia & Lymphoma Society's beginning 70 years ago with the development of new treatments for childhood leukemia to today's advances in precision medicine and immunotherapy, LLS has led the way in changing the way we treat cancer and care for patients."

To learn more about LLS's Students of the Year program visit: www.studentseries.org.

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

 

SOURCE The Leukemia & Lymphoma Society's (LLS) Silicon Valley & Monterey Bay Area Chapter


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: